Metabolic Reprogramming of Cancer-Associated Fibroblast in the Tumor Microenvironment: From Basics to Clinic [0.03%]
肿瘤微环境癌相关成纤维细胞的代谢重塑：从基础到临床
Lujia Zhou,Wenjie Zhang,Xiaoxue Hu et al.
Lujia Zhou et al.
Metabolic reprogramming occurs when tumor cells replenish themselves with nutrients required for growth to meet their metabolic needs. Cancer-associated fibroblasts (CAFs) are activated fibroblasts involved in building the c (TME) to promot...
Potential Role of AKR1B1 Gene Methylation in Diagnosis of Patients With Breast Cancer [0.03%]
乙醛脱氢酶基因甲基化在乳腺癌诊断中的潜在作用研究
Mohamed El-Far,Mohamed A Abdelrazek,Basma M Foda et al.
Mohamed El-Far et al.
Background: In addition to the great challenge of early diagnosis and prognosis in breast cancer (BC), the role of gene promoters in BC remains largely unexplored. This study aimed to evaluate aldo-keto reductase family 1...
Early-Stage Renal Cell Carcinoma Locoregional Therapies: Current Approaches and Future Directions [0.03%]
早期肾细胞癌局部治疗：当前方法与未来方向
Umang Khandpur,Bereket Haile,Mina S Makary
Umang Khandpur
Renal cell carcinoma (RCC) is the most common primary renal malignancy. Prevalence of RCC in developed countries has slowly increased. Although partial or total nephrectomy has been the first-line treatment for early-stage RCC, improved or ...
Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity [0.03%]
RPL3在BRCA相关癌症中的临床意义探究：揭示其与癌症免疫的相互作用
Linyi Wang,Minlong Chen,Zhaosheng Ma et al.
Linyi Wang et al.
Background: Few studies have explored the expression profile of RPL3 in breast cancer (BRCA). Our research provided an in-depth analysis of RPL3 expression patterns in BRCA, highlighting its significance for therapy predi...
Dendritic Cells Loaded With Heat Shock Inactivated Glioma Stem Cells Enhance Antitumor Response of Mouse Glioma When Combining With CD47 Blockade [0.03%]
热休克灭活的胶质瘤干细胞负载树突状细胞联合阻断CD47抗胶质瘤效应增强
Qijia Tan,Feng Li,Jun Wang et al.
Qijia Tan et al.
Background: For glioma patients, the long-term advantages of dendritic cells (DCs) immunization remain unknown. It is extremely important to develop new treatment strategies that enhance the immunotherapy effect of DC-bas...
Expression of CREBBP and EP300 Associated With Tumor Volume in Patients With Grade-3 Glioma: A Retrospective Analysis [0.03%]
CBP和EP300在三级胶质瘤患者中的表达与肿瘤体积相关：回顾性分析
Cuiwei Chen,Meiqin Yuan,Liang Xia et al.
Cuiwei Chen et al.
Background: Reliable predictive data are crucial for making accurate treatment decisions in glioma patients, but it can be challenging to obtain due to limited information in many cases. Numerous research studies have ind...
Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck [0.03%]
联合阳性计分和顺铂敏感性是复发转移型头颈部鳞癌纳武单抗治疗反应的预后因素
Hiroaki Iijima,Akihiro Sakai,Koji Ebisumoto et al.
Hiroaki Iijima et al.
Background: Recurrent or metastatic squamous cell carcinoma of the head and neck (R/MHNSCC) is a challenging malignancy with a poor prognosis and limited treatment options. Nivolumab, an immune checkpoint inhibitor (ICI) ...
Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers [0.03%]
循环肿瘤DNA在检测肺癌突变和指导靶向治疗中的应用价值
Kun Li,Nana Zhang,Bing Xu et al.
Kun Li et al.
Background: Tumor genomic profiling has a significant impact on the selection of targeted therapy. Circulating tumor DNA (ctDNA) has emerged as a noninvasive, and reproducible assay compared with tissue biopsy. We aimed t...
Comparison and Analysis of Clinical Features of Papillary Thyroid Cancer Complicated With Hashimoto's Thyroiditis [0.03%]
桥本甲状腺炎合并乳头状甲状腺癌的临床特征分析
Ke Zheng,Jingxin Mao
Ke Zheng
Background: Hashimoto thyroiditis (HT) combined with papillary thyroid cancer (PTC) is more common in clinical practice, maybe posing a serious threat to the health of patients. It is uncertain whether HT is a risk factor...
An Active Trend of Immunotherapy Combination Regimen as Second-Line Therapy Towards Advanced Biliary Tract Cancer [0.03%]
免疫治疗联合方案作为胆道癌二线治疗的积极趋势分析
Haimin Weng,Pengfei Zeng,Yuemiao Chen et al.
Haimin Weng et al.
Background: As a second-line therapy, oxaliplatin/fluorouracil/leucovorin (FOLFOX) remains the standard of care for patients with biliary tract cancer (BTC); however, its efficacy is suboptimal. The aim of this study was ...